Varma Mutual Pension Insurance Co Has $61 Million Stake in AbbVie Inc. $ABBV

Varma Mutual Pension Insurance Co increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 8.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 263,467 shares of the company’s stock after acquiring an additional 21,200 shares during the period. Varma Mutual Pension Insurance Co’s holdings in AbbVie were worth $61,003,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA grew its stake in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC increased its holdings in AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC increased its holdings in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its holdings in shares of AbbVie by 0.6% during the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record Q4 net sales and upbeat guidance reinforce AbbVie’s diversified growth story (Skyrizi/Rinvoq strength and overall revenue beat), supporting longer-term earnings visibility. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $250 price target following the strong quarter, signaling continued analyst confidence that could support the share price. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: AbbVie’s real‑world migraine (ubrogepant) study could expand market potential for its acute migraine franchise, a constructive long-term revenue opportunity if outcomes are favorable. AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential
• Neutral Sentiment: Clinical program update: AbbVie posted a Phase 2 elezanumab study update in acute cervical spinal cord injury — relevant for pipeline upside but data are early and timing/impact remain uncertain. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Operational repositioning: coverage suggests AbbVie is reshaping U.S. operations with Medicaid concessions to prioritize growth categories — could ease payer tensions but may compress near-term margins. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus
• Negative Sentiment: AbbVie sued HHS over CMS selecting Botox for Medicare price cuts under the Inflation Reduction Act — the dispute highlights material regulatory risk to Botox revenue and creates legal uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Evercore ISI trimmed its price target modestly (while keeping Outperform), and broader analyst chatter highlights valuation/forecast risk — small downgrades can pressure sentiment after a rally. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Competitive pressure: heavy TV ad spending for J&J’s Tremfya (and continued promotion of rivals) raises marketing intensity in immunology, which could cap near‑term share gains for Rinvoq/Skyrizi. J&J’s Tremfya roars into 2026 with massive TV ad spend, trailed by AbbVie’s Rinvoq and Skyrizi

Analysts Set New Price Targets

ABBV has been the subject of several research analyst reports. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Evercore decreased their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. UBS Group cut their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Finally, Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Stock Down 0.8%

NYSE:ABBV opened at $220.74 on Thursday. The stock has a market cap of $390.12 billion, a price-to-earnings ratio of 93.53, a PEG ratio of 0.77 and a beta of 0.35. The company’s 50 day moving average price is $223.47 and its 200-day moving average price is $220.29. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.